Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosis of non-small cell lung cancer * Stage IIIB or IV disease * Eligible for second-line docetaxel * Disease progression during or after completion of prior first-line therapy comprising radiotherapy and/or platinum-based chemotherapy PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-1 Life expectancy * At least 2 months Hematopoietic * Neutrophil count \> 1,500/mm\^3 * Platelet count \> 100,000/mm\^3 * WBC \> 3,000/mm\^3 * No history of thrombotic thrombocytopenic purpura or other platelet disease Hepatic * Bilirubin normal * ALT and AST ≤ 2.5 times upper limit of normal (ULN) (1.5 times ULN if alkaline phosphatase \> 2.5 times ULN) * Alkaline phosphatase ≤ 5 times ULN (unless bone metastases are present) * PT \< 1.5 times ULN * Activated PTT normal Renal * Creatinine clearance or glomerular filtration rate \> 50mL/min Cardiovascular * None of the following within the past 3 months: * Myocardial infarction * Stroke * Congestive heart failure Immunologic * No history of immune-mediated thrombocytopenia * No evidence of anti-heparin antibodies * No history of allergy and/or hypersensitivity to anti-coagulants or thrombolytic agents, especially heparin * No history of allergy to polysorbate 80 * No uncontrolled or serious infection within the past 4 weeks Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * See Disease Characteristics * No prior docetaxel Endocrine therapy * Not specified Radiotherapy * See Disease Characteristics * More than 3 months since prior radiotherapy to \> 30% of marrow-bearing bone * Concurrent local palliative radiotherapy allowed Surgery * More than 4 weeks since prior major surgery Other * More than 4 weeks since prior antineoplastic therapy * More than 2 weeks since prior and no concurrent heparin or low-molecular weight heparin * More than 4 weeks since prior investigational therapy * No concurrent aspirin or aspirin-containing medications except low-dose aspirin (≤ 100 mg/day) * No concurrent nonsteroidal anti-inflammatory drugs except cyclooxygenase-2 inhibitors * No concurrent warfarin or warfarin-containing medications except low-dose warfarin (≤ 1 mg/day) * No concurrent antiplatelet drugs, including any of the following: * Abciximab * Clopidogrel * Dipyridamole * Ticlopidine * Tirofiban * No concurrent drugs that may inhibit docetaxel metabolism, including any of the following: * Cyclosporine * Terfenadine * Ketoconazole * Erythromycin * Troleandomycin * No other concurrent investigational drugs * No other concurrent antineoplastic therapy